Publication:
Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration

dc.contributor.authorBEKİROĞLU, GÜLNAZ NURAL
dc.contributor.authorsUenver, Y. B.; Yavuz, G. A.; Bekiroglu, N.; Presti, P.; Li, W.; Sinclair, S. H.
dc.date.accessioned2022-03-14T09:04:44Z
dc.date.accessioned2026-01-11T11:27:12Z
dc.date.available2022-03-14T09:04:44Z
dc.date.issued2009-02
dc.description.abstractPurpose This pilot study was undertaken to examine the relationships between clinical measures of visual function and anatomic changes occurring in the eyes treated with bevacizumab for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Methods A retrospective review was conducted for 50 eyes that had been treated with at least three injections of bevicizumab for CNV due to AMD, and followed for at least 6 months. Vision outcomes included best-corrected ETDRS chart acuity, scored by best-line read (ETDRS line) and by total letters read (ETDRS letter), and two measures obtained from central acuity perimetry with 98% Michelson contrast targets, the best acuity within 6 degrees of fixation (BA6 degrees), and global macular acuity (GMA), representing a weighted average of the acuities thresholded at all intercepts within a 10 degrees radius of fixation. Assessment of anatomic outcomes included fibrosis, atrophy, and subretinal hemorrhage grading on fundus photography, CNV size, pigment epithelial detachment (PED) size and grading of CNV leakage on fluorescein angiography, and central retinal PED, and subretinal fluid (SRF) thickness on optical coherence tomography. Results Logistic regression analysis showed an association between the vision outcomes of EDTRS letter and BA6 degrees with the change in SRF thickness (R-2: 0.47 and 0.35, respectively). The outcome of the vision measurement of GMA was associated with the change in SRF thickness, in CNV thickness, and in CNV fibrosis grade (R-2: 0.34). No association was noted between the outcomes of ETDRS line with the change in any anatomic outcomes. Conclusion Acuity perimetry outcomes in this study seemed to offer improved understanding of the relationship between the vision outcomes and the measured anatomic changes. It seemed that neither ocular coherence tomography nor fluorescein angiography alone offered sufficient morphologic markers for prediction of functional outcomes.
dc.identifier.doi10.1038/eye.2008.349
dc.identifier.eissn1476-5454
dc.identifier.issn0950-222X
dc.identifier.pubmed19039333
dc.identifier.urihttps://hdl.handle.net/11424/242414
dc.identifier.wosWOS:000263321000035
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.relation.ispartofEYE
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectage-related macular degeneration
dc.subjectanatomic outcome
dc.subjectbevacizumab
dc.subjectavastin treatment
dc.subjectvision outcome
dc.subjectcentral field acuity testing
dc.subjectOPTICAL COHERENCE TOMOGRAPHY
dc.subjectINTRAVITREAL BEVACIZUMAB
dc.subjectPHOTODYNAMIC THERAPY
dc.subjectFIXATION PATTERNS
dc.subjectCENTRAL SCOTOMAS
dc.subjectAVASTIN
dc.subjectACUITY
dc.subjectSECONDARY
dc.subjectEYES
dc.titleRelationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage460
oaire.citation.issue2
oaire.citation.startPage453
oaire.citation.titleEYE
oaire.citation.volume23

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
223.62 KB
Format:
Adobe Portable Document Format